Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.
2.
3.

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.

Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP.

Prev Cardiol. 2006 Summer;9(3):138-43. Review.

4.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
5.

Lp-PLA2: an emerging biomarker of coronary heart disease.

Dada N, Kim NW, Wolfert RL.

Expert Rev Mol Diagn. 2002 Jan;2(1):17-22. Review.

PMID:
11963798
6.

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.

Li D, Zhao L, Yu J, Zhang W, Du R, Liu X, Liu Y, Chen Y, Zeng R, Cao Y, Zeng Z, Zhao Z, Wu J.

Clin Chim Acta. 2017 Feb;465:22-29. doi: 10.1016/j.cca.2016.12.006. Epub 2016 Dec 9. Review.

PMID:
27956130
7.

[Lipoprotein associated phospholipase A2].

Rubinstein A, Izkhakov E.

Harefuah. 2011 Feb;150(2):136-40, 205. Review. Hebrew.

PMID:
22164942
8.

The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.

Tellis CC, Tselepis AD.

Biochim Biophys Acta. 2009 May;1791(5):327-38. doi: 10.1016/j.bbalip.2009.02.015. Review.

PMID:
19272461
9.
10.

Lipoprotein-associated phospholipase A2 as a target of therapy.

Macphee CH, Nelson JJ, Zalewski A.

Curr Opin Lipidol. 2005 Aug;16(4):442-6. Review.

PMID:
15990594
11.

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.

Carlquist JF, Muhlestein JB, Anderson JL.

Expert Rev Mol Diagn. 2007 Sep;7(5):511-7. Review.

PMID:
17892360
12.
13.

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.

Zalewski A, Macphee C.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):923-31. Epub 2005 Feb 24. Review.

14.

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.

Caslake MJ, Packard CJ.

Curr Opin Lipidol. 2003 Aug;14(4):347-52. Review.

PMID:
12865731
15.

Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.

Li D, Wei W, Ran X, Yu J, Li H, Zhao L, Zeng H, Cao Y, Zeng Z, Wan Z.

Clin Chim Acta. 2017 Aug;471:38-45. doi: 10.1016/j.cca.2017.05.017. Epub 2017 May 14. Review.

PMID:
28514697
16.

Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.

Caslake MJ, Packard CJ.

Nat Clin Pract Cardiovasc Med. 2005 Oct;2(10):529-35. Review.

PMID:
16186851
17.

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Virani SS, Nambi V.

Curr Atheroscler Rep. 2007 Aug;9(2):97-103. Review.

PMID:
17877917
18.

[Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].

Bonnefont-Rousselot D.

Ann Pharm Fr. 2016 May;74(3):190-7. doi: 10.1016/j.pharma.2015.09.002. Epub 2015 Oct 21. Review. French.

PMID:
26499399
19.

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target.

Macphee CH, Nelson J, Zalewski A.

Curr Opin Pharmacol. 2006 Apr;6(2):154-61. Epub 2006 Feb 21. Review.

PMID:
16495153
20.

C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.

Tsimikas S, Willerson JT, Ridker PM.

J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C19-31. Review.

Supplemental Content

Support Center